BR0011835A - Polimorfos de cloreto de (2-benzidril-1-azabiciclo [2,2,2] Èct-3-il)-(5-isopropil-2-metoxibenzil) amÈnio cristalino como antagonistas de receptor nk-1 - Google Patents

Polimorfos de cloreto de (2-benzidril-1-azabiciclo [2,2,2] Èct-3-il)-(5-isopropil-2-metoxibenzil) amÈnio cristalino como antagonistas de receptor nk-1

Info

Publication number
BR0011835A
BR0011835A BR0011835-4A BR0011835A BR0011835A BR 0011835 A BR0011835 A BR 0011835A BR 0011835 A BR0011835 A BR 0011835A BR 0011835 A BR0011835 A BR 0011835A
Authority
BR
Brazil
Prior art keywords
èct
benzhydryl
polymorphs
methoxybenzyl
isopropyl
Prior art date
Application number
BR0011835-4A
Other languages
English (en)
Portuguese (pt)
Inventor
Douglas John Meldrum Allen
Troy Anthony Appleton
Michael Jon Gumkowski
David Joseph Muehlbauer
Timothy Norris
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BR0011835A publication Critical patent/BR0011835A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D453/00Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D455/00Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/02Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing not further condensed quinolizine ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BR0011835-4A 1999-06-22 2000-06-06 Polimorfos de cloreto de (2-benzidril-1-azabiciclo [2,2,2] Èct-3-il)-(5-isopropil-2-metoxibenzil) amÈnio cristalino como antagonistas de receptor nk-1 BR0011835A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14023399P 1999-06-22 1999-06-22
PCT/IB2000/000756 WO2000078759A1 (en) 1999-06-22 2000-06-06 Polymorphs of crystalline (2-benzhydryl-1-azabicyclo[2,2,2]oct-3-yl)-(5-isopropyl-2-methoxybenzyl)-ammoniumchloride as nk-1 receptor antagonists

Publications (1)

Publication Number Publication Date
BR0011835A true BR0011835A (pt) 2002-03-05

Family

ID=22490317

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0011835-4A BR0011835A (pt) 1999-06-22 2000-06-06 Polimorfos de cloreto de (2-benzidril-1-azabiciclo [2,2,2] Èct-3-il)-(5-isopropil-2-metoxibenzil) amÈnio cristalino como antagonistas de receptor nk-1

Country Status (35)

Country Link
US (1) US6262067B1 (cs)
EP (1) EP1187834A1 (cs)
JP (1) JP2003502425A (cs)
KR (1) KR20020030280A (cs)
CN (1) CN1390216A (cs)
AP (1) AP2001002367A0 (cs)
AR (1) AR024411A1 (cs)
AU (1) AU767336B2 (cs)
BG (1) BG106205A (cs)
BR (1) BR0011835A (cs)
CA (1) CA2375265A1 (cs)
CO (1) CO5190663A1 (cs)
CZ (1) CZ20014458A3 (cs)
DZ (1) DZ3055A1 (cs)
EA (1) EA004264B1 (cs)
EC (1) ECSP003538A (cs)
EE (1) EE200100698A (cs)
HR (1) HRP20010920A2 (cs)
HU (1) HUP0201694A3 (cs)
IL (1) IL146410A0 (cs)
IS (1) IS6161A (cs)
MA (1) MA26744A1 (cs)
MX (1) MXPA02000033A (cs)
NO (1) NO20016187L (cs)
NZ (1) NZ515348A (cs)
OA (1) OA11952A (cs)
PA (1) PA8496701A1 (cs)
PE (1) PE20010322A1 (cs)
PL (1) PL352899A1 (cs)
SK (1) SK18672001A3 (cs)
TN (1) TNSN00137A1 (cs)
TR (1) TR200103688T2 (cs)
UY (1) UY26211A1 (cs)
WO (1) WO2000078759A1 (cs)
ZA (1) ZA200110387B (cs)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6387925B1 (en) * 1999-06-01 2002-05-14 Pfizer Inc. Polymorphs of a crystalline azo-bicyclo (2.2.2) oct-3-yl amine citrate and their pharmaceutical compositions
US6756379B2 (en) * 2001-07-26 2004-06-29 Taro Pharmaceutical Industries Ltd. Non-sedating barbiturate compounds as neuroprotective agents
US7683071B2 (en) * 2000-07-26 2010-03-23 Taro Pharmaceuticals Industries Ltd. Composition and method for improved bioavailability and enhanced brain delivery of 5,5-diphenyl barbituric acid
US6939873B2 (en) * 2000-07-26 2005-09-06 Taro Pharmaceuticals Industries Limited Non-sedating barbituric acid derivatives
WO2004031191A1 (en) * 2002-10-04 2004-04-15 Merck Sharp & Dohme Limited Azabicyclic spiroether derivatives as receptor antagonists
TWI334780B (en) 2002-12-11 2010-12-21 Taro Pharmaceuticals Ireland Ltd Method of treating movement disorders using barbituric acid derivatives
CA2572797A1 (en) * 2004-07-02 2006-01-12 Daniella Gutman A process for preparing 1-methoxymethyl-5,5-diphenylbarbituric acid
EP2081576A4 (en) * 2006-11-14 2010-06-30 Taro Pharmaceuticals North Ame METHOD FOR IMPROVING BIOAVAILABILITY FOR NON-EDMING BARBITURATES
UA102128C2 (en) * 2008-12-05 2013-06-10 Х. Луннбек А/С Nalmefene hydrochloride dihydrate
CN114423752B (zh) * 2019-06-03 2025-06-24 耶路撒冷希伯来大学伊萨姆研究发展公司 吡唑化合物的非吸湿性结晶盐和其药物组合物与用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990005525A1 (en) * 1988-11-23 1990-05-31 Pfizer Inc. Quinuclidine derivatives as substance p antagonists
KR100214905B1 (ko) * 1991-05-31 1999-08-02 디. 제이. 우드, 스피겔 알렌 제이 퀴누클리딘 유도체
EP0668863B1 (en) * 1992-11-12 1997-01-08 Pfizer Inc. Quinuclidine derivative as substance p antagonist
US5393762A (en) * 1993-06-04 1995-02-28 Pfizer Inc. Pharmaceutical agents for treatment of emesis

Also Published As

Publication number Publication date
ZA200110387B (en) 2002-12-19
WO2000078759A1 (en) 2000-12-28
DZ3055A1 (fr) 2004-03-27
NO20016187D0 (no) 2001-12-18
TNSN00137A1 (fr) 2002-05-30
US6262067B1 (en) 2001-07-17
NZ515348A (en) 2003-07-25
OA11952A (en) 2006-04-13
CA2375265A1 (en) 2000-12-28
HUP0201694A2 (en) 2002-09-28
MA26744A1 (fr) 2004-12-20
PE20010322A1 (es) 2001-03-14
MXPA02000033A (es) 2002-07-02
AR024411A1 (es) 2002-10-02
CN1390216A (zh) 2003-01-08
AU767336B2 (en) 2003-11-06
JP2003502425A (ja) 2003-01-21
HRP20010920A2 (en) 2003-02-28
AP2001002367A0 (en) 2001-12-31
CZ20014458A3 (cs) 2002-03-13
AU4774500A (en) 2001-01-09
PL352899A1 (en) 2003-09-22
EE200100698A (et) 2003-02-17
EA200101179A1 (ru) 2002-06-27
SK18672001A3 (sk) 2002-08-06
HUP0201694A3 (en) 2002-10-28
NO20016187L (no) 2001-12-18
UY26211A1 (es) 2001-01-31
IS6161A (is) 2001-11-13
CO5190663A1 (es) 2002-08-29
IL146410A0 (en) 2002-07-25
PA8496701A1 (es) 2002-07-30
KR20020030280A (ko) 2002-04-24
EA004264B1 (ru) 2004-02-26
EP1187834A1 (en) 2002-03-20
BG106205A (bg) 2002-07-31
TR200103688T2 (tr) 2002-12-23
ECSP003538A (es) 2002-01-25

Similar Documents

Publication Publication Date Title
UA72881C2 (uk) Похідні тієнопіридину, фармацевтична композиція з використанням таких сполук (варіанти), проміжна сполука
MXPA05010859A (es) Antagonistas mchr1 heterociclicos.
BR0011835A (pt) Polimorfos de cloreto de (2-benzidril-1-azabiciclo [2,2,2] Èct-3-il)-(5-isopropil-2-metoxibenzil) amÈnio cristalino como antagonistas de receptor nk-1
BR9916980A (pt) Derivados bicìclicos substituìdos úteis como agentes anticancerìgenos
WO2003093250A3 (en) Positive allosteric modulators of the nicotinic acetylcholine receptor
IL115040A (en) Substituted piperidines useful for the treatment of allergic diseases process for their preparation and pharmaceutical compositions containing them
HU224496B1 (hu) Pirrolidin-3-il-alkil-piperidin-származékok és e vegyületeket tartalmazó gyógyászati készítmények
WO2003048164A3 (en) Adenosine a2a receptor antagonists
WO2001066534A3 (en) Cyclic and bicyclic diamino histamine-3 receptor antagonists
MXPA04005209A (es) Antagonistas del receptor de adenosina a2a.
IL142893A0 (en) Fused polyclic heterocyclic compounds and pharmaceutical compositions containing the same
NZ512526A (en) 4-sulfonamido-6-sulfamidoalkoxypyrimidine derivatives, pharmaceuticals thereof, and their use for the treatment of disorders associated with a role of endothelin.
MX9705801A (es) Derivados de acido 5-(4-piperidinil-1-sustituido)-3-arilpentaoico como antagonistas del receptor de taquicinina.
ES2032570T3 (es) Derivados antiparkinson de ergolina. (reserva del art. 167.2 cpe).
BR0011125A (pt) Polimorfos de citrato de (2-benzidril-1-azabiciclo[2.2.2]oct-3-il)-(5-iso-propil-2-m etoxibenzil)-amina cristalino como antagonistas de receptor nk-1
WO2001010860A3 (en) Quinazolinone and azaquinazolinone derivatives
Stevenson et al. Phase I/pharmacokinetic trial of the novel thioxanthone SR233377 (WIN33377) on a 5-day schedule
DE3361504D1 (en) Substituted benzodiazepinones, process for their preparation and medicines containing them
YU81101A (sh) Polimorfni oblici kristalnog citrata azabiciklo (2,2,2) oktan-3-amina i njihovih farmaceutskih kompozicija
MX2008001607A (es) Piperazinas biciclicas como antagonistas del receptor de glutamato metabotropico.
DE3571619D1 (en) 4-oxo-pyrido-û2,3-d¨pyrimidine derivatives, process for their preparation and medicaments containing them
ES2169471T3 (es) Derivados de la tetrahidroimidazo(2,1-a)isoquinolina.
MY140450A (en) New crystalline forms of 2, 3 dimethyl-8-(2,6-dimethylbenzylamino)-n-hydroxyethyl-imidazo [1,2-a] pyridine-6-carboxamide mesylate salt
PE20040066A1 (es) NUEVA FORMULACION PARA LA ADMINISTRACION PARENTERAL DE UN BLOQUEANTE DEL CANAL DEL Na
HK1195907A1 (zh) 取代的2,3-二氢咪唑并[1,2-c]喹唑啉盐

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1962 DE 12/08/2008.